Coverage from CNN, TIME, USA Today, CNBC, Gizmodo, and others
Lillys CEO Dave Ricks warned that the growth of compounding could create a backdoor generic world. This article is exclusive to STAT+ subscribers Unlock this article plus daily coverage and analysis of the pharma industry by subscribing to STAT+
Beide Abos bieten neuen Mitgliedern ein 30-tgiges kostenloses Probeabo
GLP-1 drugs, including Zepbound for weight loss , rely on steady hormone levels in the body to maintain appetite control
Saxenda delays gastric emptying, causing food to remain in the digestive system longer
It is worth reading more about how the options compare in our guide on which weight-loss treatment is right for you, and about the risks of unregistered products in our note on compounded GLP-1 medications